WO2000010546A3 - Nouveau traitement de maladies neurodegeneratives - Google Patents

Nouveau traitement de maladies neurodegeneratives Download PDF

Info

Publication number
WO2000010546A3
WO2000010546A3 PCT/EP1999/006241 EP9906241W WO0010546A3 WO 2000010546 A3 WO2000010546 A3 WO 2000010546A3 EP 9906241 W EP9906241 W EP 9906241W WO 0010546 A3 WO0010546 A3 WO 0010546A3
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
analog
treatment
cell death
diseases
Prior art date
Application number
PCT/EP1999/006241
Other languages
English (en)
Other versions
WO2000010546A2 (fr
Inventor
Maria Griselda Canteros
Osborne F X Almeida
Original Assignee
Max Planck Gesellschaft
Maria Griselda Canteros
Osborne F X Almeida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Maria Griselda Canteros, Osborne F X Almeida filed Critical Max Planck Gesellschaft
Priority to AU58547/99A priority Critical patent/AU5854799A/en
Publication of WO2000010546A2 publication Critical patent/WO2000010546A2/fr
Publication of WO2000010546A3 publication Critical patent/WO2000010546A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)

Abstract

L'invention concerne d'une manière générale la modulation de la mort cellulaire apoptotique. Elle concerne plus particulièrement des compositions pharmaceutiques comprenant de la D-arginine ou un analogue de celle-ci, particulièrement utiles pour le traitement, la prévention et/ou le retardement de la mort des cellules neuronales. Elle se rapporte encore à une méthode de traitement, de prévention et/ou de retardement de la mort de cellules neuronales chez un sujet, méthode qui consiste à administrer à un sujet de la D-arginine ou un analogue de celle-ci, et à l'utilisation de la D-arginine ou d'un analogue de celle-ci pour la préparation de compositions pharmaceutiques pour le traitement de maladies neurodégénérative. Par ailleurs, des aliments pour l'homme et pour les animaux ainsi que des compléments alimentaires associés, comprenant de la D-arginine ou un analogue de celle-ci, sont décrits, ainsi que des méthodes d'identification et de production de médicaments neuroprotecteurs.
PCT/EP1999/006241 1998-08-25 1999-08-25 Nouveau traitement de maladies neurodegeneratives WO2000010546A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58547/99A AU5854799A (en) 1998-08-25 1999-08-25 Novel treatment of neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98116035.1 1998-08-25
EP98116035 1998-08-25

Publications (2)

Publication Number Publication Date
WO2000010546A2 WO2000010546A2 (fr) 2000-03-02
WO2000010546A3 true WO2000010546A3 (fr) 2003-04-17

Family

ID=8232511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006241 WO2000010546A2 (fr) 1998-08-25 1999-08-25 Nouveau traitement de maladies neurodegeneratives

Country Status (2)

Country Link
AU (1) AU5854799A (fr)
WO (1) WO2000010546A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265825A1 (en) * 2001-01-19 2004-12-30 Boris Tartakovsky Methods and compositions for diagnosing and treating a subject having depression
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
WO2006126199A2 (fr) * 2005-05-24 2006-11-30 Fund For Medical Research Development Of Infrastructure & Health Services Rambam Medical Center Methodes et compositions pour traiter la schizophrenie
JP7078410B2 (ja) * 2018-01-31 2022-05-31 株式会社明治 Ｄ－アルギニンを含む組成物およびその製造方法。

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789681A (en) * 1985-12-23 1988-12-06 Italfarmaco S.P.A. Cytoprotective guanidine derivatives useful in ischemic diseases
DE4311806A1 (de) * 1993-04-03 1994-10-06 Schering Ag Verwendung von Argininderivaten als Quisqualatantagonisten
EP0630649A1 (fr) * 1993-06-14 1994-12-28 Zeneca Limited Combinaison d'un inhibiteur de la synthase inductible de l'oxyde nitrique avec un agent antiinflammatoire, p.ex. un corticosteroide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789681A (en) * 1985-12-23 1988-12-06 Italfarmaco S.P.A. Cytoprotective guanidine derivatives useful in ischemic diseases
DE4311806A1 (de) * 1993-04-03 1994-10-06 Schering Ag Verwendung von Argininderivaten als Quisqualatantagonisten
EP0630649A1 (fr) * 1993-06-14 1994-12-28 Zeneca Limited Combinaison d'un inhibiteur de la synthase inductible de l'oxyde nitrique avec un agent antiinflammatoire, p.ex. un corticosteroide

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CANTEROS, M.G. ET AL: "Nitric oxide mediates dexamethasone-induced apoptosis in the dentate gyrus: The protective actions of D-arginine", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, pages 1047, XP000905168 *
CORASANTI, M.T. ET AL: "Death of cultured human neuroblastoma cells induced by HIV-1 gp120 is prevented by NMDA receptor antagonists and inhibitors of nitric oxide and cyclooxygenase", NEURODEGENERATION, vol. 4, no. 3, 1995, pages 315 - 321, XP000905597 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002137131 *
ENDO, R. ET AL: "Cerebrospinal fluid vasopressin levels and the effect of 1-desamino-8-D-arginine vasopressin DDAVP in dementia", JOURNAL OF TOKYO WOMENS COLLEGE, vol. 59, no. 6, 1989, pages 615 - 619 *
FLÜGGE, G.: "Dynamics of central nervous 5-HT1A-receptors under psychosocial stress", THE JOURNAL OF NEUROSCIENCE, vol. 15, no. 11, 1995, pages 7132 - 7140, XP000905495 *
FORRAY, M. I. ET AL: "Transport of nitric oxide synthase inhibitors through cationic amino acid carriers in human erythrocytes", BIOCHEMICAL PHARMACOLOGY, vol. 50, no. 12, 1995, pages 1963 - 1968, XP000905497 *
HASSAN, A.H.S. ET AL: "Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone", EXPERIMENTAL NEUROLOGY, vol. 140, no. 1, July 1996 (1996-07-01), pages 43 - 52, XP000905487 *
KOHNO, K. ET AL: "Intraventricular administration of nitric oxide synthase inhibitors prevents delayed neuronal cell death in gerbil hippocampal CA1 neurons", NEUROSCIENCE LETTERS, vol. 199, no. 1, 1995, pages 65 - 68, XP000905496 *
MASON, R.P. ET AL: "Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells", THE JOURNAL OF NEUROCHEMISTRY, vol. 72, no. 4, April 1999 (1999-04-01), pages 1448 - 1456, XP000905185 *
MATTHEWS, R.T. ET AL: "S-methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity", EXPERIMENTAL NEUROLOGY, vol. 143, no. 2, February 1997 (1997-02-01), pages 282 - 286, XP000905617 *
POW, D.V. ET AL: "Immunocytochemical analysis of the transport of arginine into nitrergic neurons and other cells in the retina and pituitary", CELL TISSUE RESEARCH, vol. 290, no. 3, December 1997 (1997-12-01), pages 501 - 514, XP000905482 *
SHIBATA, S. ET AL: "NG-nitro-L-arginine protects against hypoxia/hypoglycemia-induced decrease in CA1 presynaptic spikes in rat hippocampal slices", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 273, no. 6, 2 June 1995 (1995-06-02), pages 223 - 228, XP000905608 *
WANG, JI-FENG ET AL: "Decreased production of reactive oxygen intermediates is an early event during in vitro apoptosis of rat thymocytes", FREE RADICAL BIOLOGY AND MEDICINE, vol. 20, no. 4, 1996, pages 533 - 542, XP000905498 *

Also Published As

Publication number Publication date
WO2000010546A2 (fr) 2000-03-02
AU5854799A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
CA2229624A1 (fr) Methode pour reduire le poids corporel et pour traiter l'obesite
WO2001095899A3 (fr) Compositions pharmaceutiques renfermant des derives de cannabidiol
WO2004011423A3 (fr) Analogues de carotenoides structuraux pour l'inhibition et la reduction de maladie
WO2002002190A3 (fr) Prevention et traitement de maladies degeneratives par le glutathion et des enzymes de detoxification de phase ii
WO2000011968A8 (fr) Composition antioxydante renfermant de l'acetyl-l-carnitine et de l'acide alpha-lipoique
IL131010A (en) Aryl sulfonamides and analogues thereof, processes for their preparation and pharmaceutical compositions comprising them in the treatment of neurodegenerative diseases
WO2001030335A3 (fr) Compositions pharmaceutiques utiles dans la prevention et le traitement d'une maladie induite par la proteine beta-amyloide
HK1085927A1 (en) The use of lupin conglutin for the preparation of a medicament, food supplements or foods for the treatment of type ii diabetes
WO1998001563A3 (fr) Proteines e4 d'adenovirus destinees a induire la mort cellulaire
WO2000008007A3 (fr) Derives de cyclopentabenzofuranne et leur utilisation
WO2000010546A3 (fr) Nouveau traitement de maladies neurodegeneratives
EP1304108A3 (fr) Compositions pour traiter l'arythmie et procédés de traitement
PL348781A1 (en) Soya extract containing lipids, process for its production, and pharmaceutical and cosmetic composition
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
WO2003002125A3 (fr) Combinaison de sucres amines et cysteine ou de derives de cysteine
EP0821969A3 (fr) Composition médicale contenant du TCF-II
Giri Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B
WO1999020291A3 (fr) Gingko biloba de qualite pharmaceutique
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
JPH08291025A (ja) 養毛料
EP1180367A4 (fr) Desodorisants contre les odeurs de sulfures de fermentation intestinale
CA2407429C (fr) Composition pour la regulation du systeme immunitaire humain et pour la prevention et le traitement de maladies de ce systeme
AU6627298A (en) Product containing idazoxan and 1-dopa as combined pharmaceutical preparation useful for treating parkinson disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase